Exiqon Preps miRNA Diagnostics for 2014 Launch, Still Needs to Find Partners | GenomeWeb

By Doug Macron

Exiqon last month provided an update on its pipeline of cancer-focused microRNA-based diagnostics, saying that it could have three tests, including ones that measure miRNA expression using biofluids, on the market within two years.

The company also released its fourth-quarter 2011 financial results, posting a small profit amid a roughly 8 percent rise in revenues.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.